UNSPSC 51433938: Nifedipine hydrochloride

This classification denotes a calcium channel blocker with the molecular formula C17H18N2O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9626V3KSPM, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 3,5-dimethyl ester, hydrochloride (1:1), but more generally known as nifedipine hydrochloride, which bears US NIH Compound Identifier 63011.

European Medicines Agency schedules nifedipine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09253MIG. Most nations, for tariff purposes, schedule nifedipine hydrochloride under HS 29333999. SMILES: CC1=C(C(C(=C(N1)C)C(=O)OC)C2CCCCC2[N+](=O)[O-])C(=O)OC.CL.

UNSPSC 51433938 Nifedipine hydrochloride, a Commodity code, encompasses pharmaceutical procurement by state and local governments for emergency medical services, public health programs, and health benefit administration. State and local buyers under this code source individual active pharmaceutical ingredients and finished-dose medications through both direct procurement for immediate operational use and cooperative purchasing frameworks that aggregate demand across multiple jurisdictions. Issuing bodies include municipal fire and emergency services departments, state health and human services agencies, and multistate cooperative purchasing alliances administering health benefit programs for state employees and participating local entities.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications including epinephrine, labetalol, adenosine, and diltiazem for Tampa Fire Rescue, with a $40,000 estimated contract value, firm pricing including freight to Tampa, nine-month minimum shelf life, one-year initial term, and a Small Local Business Enterprise sheltered market designation offering a five percent bid discount. The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers, comply with cGMP and DSCSA, and accept a three percent administrative fee, with contract terms of two years effective July 1, 2026.